The Marijuana Diet? Scientists find link between pot smoking and weight loss

“Low levels of insulin associated with users of marijuana. Vast ramifications seen.”

NR

 

“Smoking refer can help you better metabolize fats and carbs.

Go ahead, take another toke — the munchies don’t make you fat.

That’s the conclusion of a report published in the American Journal of Medicine, which found a strong correlation between marijuana use and a smaller waistband.

The study, conducted by researchers from the University of Nebraska, Harvard and Beth Israel Deaconess Medical Center, examined 4,657 adults, 579 of whom regularly smoked reefer.

“We found significant associations between marijuana use and smaller waist circumferences,” the researchers report.

Specifically, potheads had 16% lower levels of insulin than their non-smoking peers.

The hormone regulates metabolism of fat and carbs. The Atlantic noted that the findings perhaps explain why smokers of the wacky tobacky are less prone to diabetes.

Even people who had smoked weed in the past but did not currently puff showed similar, though less striking, results.”

 http://www.nydailynews.com/life-style/health/smoke-pot-thin-article-1.1345812

Could marijuana reduce diabetes risk? – Fox News

“There’s an unexpected link between marijuana use and factors related to Type 2 diabetes that has medical researchers intrigued.”
Smoking marijuana_Reuters_Feb 6 2013.jpg

“Several studies have found that marijuana users take in more food calories than nonusers, but they still have lower rates of obesity and diabetes, and lower average body mass index (BMI) levels.

In a new study, researchers investigated what effects marijuana and its active ingredient tetrahydrocannabinol (THC) might have on people’s metabolism, especially insulin levels.

Insulin resistance an important risk factor for diabetes is a metabolic disorder that occurs when the body’s cells cannot properly intake insulin. The American Heart Association estimates 35 percent of U.S. adults have metabolic disorders that include insulin resistance.

To examine the link between THC and metabolism, researchers gathered the results of 4,657 adults from the National Health and Nutrition Examination Survey, a cross-sectional study administered annually by the Centers for Disease Control and Prevention.

Of the study’s participants, 579 were current marijuana users, 1,975 had used the drug in the past but not recently, and 2,103 had never tried marijuana. Researchers analyzed the participants’ fasting insulin levels, cholesterol levels, insulin resistance and waist sizes.

Multiple benefits seen”

Read more: http://www.foxnews.com/health/2013/05/16/could-marijuana-reduce-diabetes-risk/

Marijuana Helps Control Diabetes, Promotes Good Cholesterol, Leads to Lower Waist Size, and Lowers Bladder Cancer Risk, New Studies Show

“Smoking marijuana has “remarkable” effect on diabetic problems and may lower risk of getting the disease, a study published on Wednesday states

pot-rx-bottle-nt.jpg

“This news comes a few days after a presentation at the annual conference of the American Urological Association that links heavy pot use to a much lower risk of bladder cancer…The more pot, the better: Researchers found that people who used marijuana more than 500 times a year were better off as far as bladder-cancer risk than those who used it infrequently.Whatever problems marijuana may cause, diabetes and bladder cancer apparently aren’t among them.”

 More: http://blogs.phoenixnewtimes.com/valleyfever/2013/05/marijuana_helps_control_diabet.php

Smoking cannabis could reduce the risk of diabetes by controlling blood sugar

“People who regularly smoke cannabis may have a lower risk of developing diabetes, new research suggests.”
 
Marijuana users had significantly lower levels of the hormone insulin - indicating better blood sugar control“Marijuana users had significantly lower levels of the hormone insulin – indicating better blood sugar control… could pave the way for the development of treatments using the plant’s compound active ingredient, tetrahydrocannabinol, or THC.

Marijuana users had 16% lower fasting insulin levels than non-users.

They were also less likely to be insulin resistant and had smaller waists.

Previous research has found cannabis smokers are less likely to be obese.”

Read more: http://www.dailymail.co.uk/health/article-2324743/Smoking-cannabis-reduce-risk-diabetes-controlling-blood-sugar.html 

The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults – The American Journal of Medicine

“There are limited data regarding the relationship between cannabinoids and metabolic processes. Epidemiologic studies have found lower prevalence rates of obesity and diabetes mellitus in marijuana users compared with people who have never used marijuana, suggesting a relationship between cannabinoids and peripheral metabolic processes. To date, no study has investigated the relationship between marijuana use and fasting insulin, glucose, and insulin resistance…

Conclusions

We found that marijuana use was associated with lower levels of fasting insulin and HOMA-IR, and smaller waist circumference…”

http://www.amjmed.com/article/S0002-9343(13)00200-3/fulltext

Smoking Marijuana May Lower Diabetes and Obesity Risk

“Marijuana may lower the risk of diabetes, according to a new study that revealed people who regularly smoked marijuana had significantly better blood sugar control.”

marijuana, cannabis, drug, addiction, weed
 
“Researchers explained that regular marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, indicating they had better sugar control.

The study published in The American Journal of Medicine included data from 4,657 patients who had answered questions on drug use.  According to the study, 579 of the patients were current marijuana users, 1,975 had used marijuana in the past and 2,103 had never used.  Researchers measured all participants’ fasting insulin and glucose levels.

Researchers found that regular marijuana users had 16 percent lower fasting insulin levels than people who had never smoke marijuana.  Marijuana users were also more likely to have a smaller waist circumference.  Previous studies have linked a large waist circumference to diabetes risk.

The study also found that participants who reported using marijuana in the past had lower levels of fasting insulin and HOMA-IR and higher levels of high-density lipoprotein cholesterol (HDL-C).  However, these correlations were weaker in people who reported using marijuana at least once, but not in the past thirty days.  The findings suggest that the impact of marijuana use on insulin and insulin resistance exists during periods of recent use.

For centuries, marijuana has been used to relieve pain, boost mood and increase appetite.  Now, medical marijuana is often used by patients suffering cancer, multiple sclerosis and other painful conditions.

If the latest findings are confirmed, researchers said the study could lead to the development of new diabetes treatments using marijuana’s compound active ingredient, tetrahydrocannabinol, or THC.

Past epidemiologic studies revealed that marijuana users had lower rates of obesity and diabetes mellitus compared to people who have never used the drug.  Researchers said that previous findings suggest a link between cannabinoids and peripheral metabolic processes, but the latest study was the first to look at the relationship between marijuana use and fasting insulin, glucose, and insulin resistance.

“It is possible that the inverse association in fasting insulin levels and insulin resistance seen among current marijuana users could be in part due to changes in usage patterns among those with a diagnosis of diabetes (i.e., those with diabetes may have been told to cease smoking). However, after we excluded those subjects with a diagnosis of diabetes mellitus, the associations between marijuana use and insulin levels, HOMA-IR, waist circumference, and HDL-C were similar and remained statistically significant,” researcher Dr. Elizabeth Penner, said in a news release.

“These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions,” American Journal of Medicine editor-in-chief Dr. Joseph Alpert wrote in an accompanying editorial.

“We desperately need a great deal more basic and clinical research into the short- and long-term effects of marijuana in a variety of clinical settings such as cancer, diabetes, and frailty of the elderly,” continues Alpert.” I would like to call on the NIH and the DEA to collaborate in developing policies to implement solid scientific investigations that would lead to information assisting physicians in the proper use and prescription of THC in its synthetic or herbal form,” he added.”

http://www.counselheal.com/articles/5381/20130515/smoking-marijuana-lower-diabetes-obesity-risk.htm

Cannabis and Δ(9)-tetrahydrocannabinol (THC) for weight loss?

“Obesity is one of the highest preventable causes of morbidity and mortality in the developed world. It has been well known for a long time that exposure to cannabis produces an increase of appetite (a phenomenon referred to as the ‘munchies’).

This phenomenon led to an exploration of the role of the endocannabinoid system in the regulation of obesity and associated metabolic syndrome. This effort subsequently led to the development of a successful therapeutic approach for obesity that consisted of blocking the cannabinoid CB(1) receptors using ligands such as Rimonabant in order to produce weight loss and improve metabolic profile. Despite being efficacious, Rimonabant was associated with increased rates of depression and anxiety and therefore removed from the market.

We recently discovered that the prevalence of obesity is paradoxically much lower in cannabis users as compared to non-users and that this difference is not accounted for by tobacco smoking status and is still present after adjusting for variables such as sex and age.

 Here, we propose that this effect is directly related to exposure to the Δ(9)-tetrahydrocannabinol (THC) present in cannabis smoke. We therefore propose the seemingly paradoxical hypothesis that THC or a THC/cannabidiol combination drug may produce weight loss and may be a useful therapeutic for the treatment of obesity and its complications.”

http://www.ncbi.nlm.nih.gov/pubmed/23410498

Endocannabinoids and obesity.

“A safe and effective antiobesity drug is needed to combat the global obesity epidemic. The discovery of cannabinoids from medicinal herbs has revealed the endocannabinoid system (ECS) in animals and humans, which regulates various physiological activities such as feeding, thermogenesis, and body weight (BW).

Although cannabinoid receptors 1 (CB1) antagonists have shown antiobesity efficacies in animal models and in the clinic, they failed to establish as a treatment due to their psychological side effects.

 Recent studies indicate that CB1 in various peripheral tissues may mediate some of the therapeutic effects of CB1 antagonists, such as improved lipid and glucose homeostasis.

 It rationalizes the development of compounds with limited brain penetration, for minimizing the side effects while retaining the therapeutic efficacies. A survey of the literature has revealed some controversies about how the ECS affects obesity. This review summarizes the research progresses and discusses some future perspectives.”

http://www.ncbi.nlm.nih.gov/pubmed/23374723

The role of the pancreatic endocannabinoid system in glucose metabolism.

“The endogenous cannabinoid system participates in the regulation of energy homeostasis, and this fact led to the identification of a new group of therapeutic agents for complicated obesity and diabetes. Cannabinoid receptor antagonists are now realities in clinical practice. The use of such antagonists for reducing body weight gain, lowering cholesterol and improving glucose homeostasis is based on the ability of the endocannabinoids to coordinately regulate energy homeostasis by interacting with central and peripheral targets, including adipose tissue, muscle, liver and endocrine pancreas. In this review we will analyse the presence of this system in the main cell types of the islets of Langerhans, as well as the physiological relevance of the endocannabinoids and parent acylethanolamides in hormone secretion and glucose homeostasis. We will also analyse the impact that these findings may have in clinical practice and the potential outcome of new therapeutic strategies for modulating glucose homeostasis and insulin/glucagon secretion.”

http://www.ncbi.nlm.nih.gov/pubmed/19285263

Presence of functional cannabinoid receptors in human endocrine pancreas.

“We examined the presence of functional cannabinoid receptors 1 and 2 (CB1, CB2) in isolated human islets, phenotyped the cells producing cannabinoid receptors and analysed the actions of selective cannabinoid receptor agonists on insulin, glucagon and somatostatin secretion in vitro. We also described the localisation on islet cells of: (1) the endocannabinoid-producing enzymes N-acyl-phosphatidyl ethanolamine-hydrolysing phospholipase D and diacylglycerol lipase; and (2) the endocannabinoid-degrading enzymes fatty acid amidohydrolase and monoacyl glycerol lipase.

RESULTS:

Human islets of Langerhans expressed CB1 and CB2 (also known as CNR1 and CNR2) mRNA and CB1 and CB2 proteins, and also the machinery involved in synthesis and degradation of 2-AG (the most abundant endocannabinoid, levels of which were modulated by glucose). Immunofluorescence revealed that CB1 was densely located in glucagon-secreting alpha cells and less so in insulin-secreting beta cells. CB2 was densely present in somatostatin-secreting delta cells, but absent in alpha and beta cells. In vitro experiments revealed that CB1 stimulation enhanced insulin and glucagon secretion, while CB2 agonism lowered glucose-dependent insulin secretion, showing these cannabinoid receptors to be functional.

CONCLUSIONS/INTERPRETATION:

Together, these results suggest a role for endogenous endocannabinoid signalling in regulation of endocrine secretion in the human pancreas.”

http://www.ncbi.nlm.nih.gov/pubmed/18092149